The FDA will offer priority review to Genentech’s supplemental biologics-license application (sBLA) application for Rituxan for children with two rare blood vessel disorders.
The Roche subsidiary’s sBLA covers Rituxan’s use in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older.
The FDA offers priority review to drugs that have the might provide significant benefits in the treatments of serious diseases.
